Cargando…
Electroclinical Features of Epilepsy in Mucopolysaccharidosis III: Outcome Description in a Cohort of 15 Italian Patients
Mucopolysaccharidosis III (Sanfilippo syndromes) types A–D are rare lysosomal storage disorders characterized by heparan sulfate accumulation and neurodegeneration. Patients with MPS III present with developmental stagnation and/or regression, sleep disturbance, and behavioral abnormalities usually...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8326392/ https://www.ncbi.nlm.nih.gov/pubmed/34349725 http://dx.doi.org/10.3389/fneur.2021.705423 |
_version_ | 1783731806775803904 |
---|---|
author | Barone, Rita Fiumara, Agata Gulisano, Mariangela Cirnigliaro, Lara Cocuzza, Maria Donatella Guida, Claudia Pettinato, Fabio Greco, Filippo Elia, Maurizio Rizzo, Renata |
author_facet | Barone, Rita Fiumara, Agata Gulisano, Mariangela Cirnigliaro, Lara Cocuzza, Maria Donatella Guida, Claudia Pettinato, Fabio Greco, Filippo Elia, Maurizio Rizzo, Renata |
author_sort | Barone, Rita |
collection | PubMed |
description | Mucopolysaccharidosis III (Sanfilippo syndromes) types A–D are rare lysosomal storage disorders characterized by heparan sulfate accumulation and neurodegeneration. Patients with MPS III present with developmental stagnation and/or regression, sleep disturbance, and behavioral abnormalities usually in the first years of life. Epilepsy may occur in a proportion of patients during the disease course. However, the progression of epilepsy and EEG changes in MPS III have not been systematically investigated. We report electroclinical features in a cohort of patients with MPS III over a follow-up period ranging from 6.5 to 22 years. Participants include 15 patients (11 females; aged 7–31 years) with MPS III A (n = 7, 47%), MPS III B (n = 5, 34%), MPS III C (n = 2, 13%), and MPS III D (n = 1, 6%). At the time of this study, 8 out of 15 patients (53%) had epilepsy. Epilepsy occurred in patients with advanced disease even in the first decade of life (mean age at onset: 12.1 ± 6.7 years). However, seizure onset may also be associated with abrupt worsening of the neurobehavioral phenotype. The main epilepsy types observed were generalized (four out of eight, 50%), followed by focal (three out of eight, 37%) and combined (two out of eight, 25%) epilepsy and status epilepticus (one out of eight, 12.5%). Seizures were generally controlled by one antiepileptic drug (AED) and most patients (seven out of eight, 87%) were still on therapy after a median follow-up period of 5 years (range: 1–9 years). A total of 66 EEGs were analyzed with a median EEG follow-up duration of 7 years (range: 6 months−14 years). Slowing of the background activity occurred in 7 (46%) patients aged 4–19 years. Epileptiform EEG abnormalities were observed in 10 patients at a mean age of 9.6 ± 2.9 years. EEG epileptiform discharges were not unavoidably linked to epilepsy. Early recognition and careful monitoring of electroclinical features in MPS III is necessary for appropriate care and for the detection of disease progression. |
format | Online Article Text |
id | pubmed-8326392 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-83263922021-08-03 Electroclinical Features of Epilepsy in Mucopolysaccharidosis III: Outcome Description in a Cohort of 15 Italian Patients Barone, Rita Fiumara, Agata Gulisano, Mariangela Cirnigliaro, Lara Cocuzza, Maria Donatella Guida, Claudia Pettinato, Fabio Greco, Filippo Elia, Maurizio Rizzo, Renata Front Neurol Neurology Mucopolysaccharidosis III (Sanfilippo syndromes) types A–D are rare lysosomal storage disorders characterized by heparan sulfate accumulation and neurodegeneration. Patients with MPS III present with developmental stagnation and/or regression, sleep disturbance, and behavioral abnormalities usually in the first years of life. Epilepsy may occur in a proportion of patients during the disease course. However, the progression of epilepsy and EEG changes in MPS III have not been systematically investigated. We report electroclinical features in a cohort of patients with MPS III over a follow-up period ranging from 6.5 to 22 years. Participants include 15 patients (11 females; aged 7–31 years) with MPS III A (n = 7, 47%), MPS III B (n = 5, 34%), MPS III C (n = 2, 13%), and MPS III D (n = 1, 6%). At the time of this study, 8 out of 15 patients (53%) had epilepsy. Epilepsy occurred in patients with advanced disease even in the first decade of life (mean age at onset: 12.1 ± 6.7 years). However, seizure onset may also be associated with abrupt worsening of the neurobehavioral phenotype. The main epilepsy types observed were generalized (four out of eight, 50%), followed by focal (three out of eight, 37%) and combined (two out of eight, 25%) epilepsy and status epilepticus (one out of eight, 12.5%). Seizures were generally controlled by one antiepileptic drug (AED) and most patients (seven out of eight, 87%) were still on therapy after a median follow-up period of 5 years (range: 1–9 years). A total of 66 EEGs were analyzed with a median EEG follow-up duration of 7 years (range: 6 months−14 years). Slowing of the background activity occurred in 7 (46%) patients aged 4–19 years. Epileptiform EEG abnormalities were observed in 10 patients at a mean age of 9.6 ± 2.9 years. EEG epileptiform discharges were not unavoidably linked to epilepsy. Early recognition and careful monitoring of electroclinical features in MPS III is necessary for appropriate care and for the detection of disease progression. Frontiers Media S.A. 2021-07-19 /pmc/articles/PMC8326392/ /pubmed/34349725 http://dx.doi.org/10.3389/fneur.2021.705423 Text en Copyright © 2021 Barone, Fiumara, Gulisano, Cirnigliaro, Cocuzza, Guida, Pettinato, Greco, Elia and Rizzo. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Neurology Barone, Rita Fiumara, Agata Gulisano, Mariangela Cirnigliaro, Lara Cocuzza, Maria Donatella Guida, Claudia Pettinato, Fabio Greco, Filippo Elia, Maurizio Rizzo, Renata Electroclinical Features of Epilepsy in Mucopolysaccharidosis III: Outcome Description in a Cohort of 15 Italian Patients |
title | Electroclinical Features of Epilepsy in Mucopolysaccharidosis III: Outcome Description in a Cohort of 15 Italian Patients |
title_full | Electroclinical Features of Epilepsy in Mucopolysaccharidosis III: Outcome Description in a Cohort of 15 Italian Patients |
title_fullStr | Electroclinical Features of Epilepsy in Mucopolysaccharidosis III: Outcome Description in a Cohort of 15 Italian Patients |
title_full_unstemmed | Electroclinical Features of Epilepsy in Mucopolysaccharidosis III: Outcome Description in a Cohort of 15 Italian Patients |
title_short | Electroclinical Features of Epilepsy in Mucopolysaccharidosis III: Outcome Description in a Cohort of 15 Italian Patients |
title_sort | electroclinical features of epilepsy in mucopolysaccharidosis iii: outcome description in a cohort of 15 italian patients |
topic | Neurology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8326392/ https://www.ncbi.nlm.nih.gov/pubmed/34349725 http://dx.doi.org/10.3389/fneur.2021.705423 |
work_keys_str_mv | AT baronerita electroclinicalfeaturesofepilepsyinmucopolysaccharidosisiiioutcomedescriptioninacohortof15italianpatients AT fiumaraagata electroclinicalfeaturesofepilepsyinmucopolysaccharidosisiiioutcomedescriptioninacohortof15italianpatients AT gulisanomariangela electroclinicalfeaturesofepilepsyinmucopolysaccharidosisiiioutcomedescriptioninacohortof15italianpatients AT cirnigliarolara electroclinicalfeaturesofepilepsyinmucopolysaccharidosisiiioutcomedescriptioninacohortof15italianpatients AT cocuzzamariadonatella electroclinicalfeaturesofepilepsyinmucopolysaccharidosisiiioutcomedescriptioninacohortof15italianpatients AT guidaclaudia electroclinicalfeaturesofepilepsyinmucopolysaccharidosisiiioutcomedescriptioninacohortof15italianpatients AT pettinatofabio electroclinicalfeaturesofepilepsyinmucopolysaccharidosisiiioutcomedescriptioninacohortof15italianpatients AT grecofilippo electroclinicalfeaturesofepilepsyinmucopolysaccharidosisiiioutcomedescriptioninacohortof15italianpatients AT eliamaurizio electroclinicalfeaturesofepilepsyinmucopolysaccharidosisiiioutcomedescriptioninacohortof15italianpatients AT rizzorenata electroclinicalfeaturesofepilepsyinmucopolysaccharidosisiiioutcomedescriptioninacohortof15italianpatients |